Molly Burich: How to Improve Biosimilar Uptake

Molly Burich, MS, head of public policy at Boehringer Ingelheim, discusses several tactics that would help increase biosimilar uptake in the United States and get around current obstacles during the World Biosimilar Congress USA 2020 at the Festival of Biologics USA in San Diego, California.
May 05, 2020

Molly Burich, MS, is the head of public policy at Boehringer Ingelheim.

With all the obstacles to biosimilar competition, where is the work around to other solutions? 

There's no question that there's barriers to the uptake of biosimilars. We have reimbursement systems that can have a tendency to incent a higher cost product. So, what we need to see are some efforts at the federal and payer level that will allow some of those misaligned incentives to be removed or adjusted to get the biosimilar market moving. Some of those ideas can include things like shared savings, where you give physicians and patients an opportunity to share some of the savings that are generated from using lower cost products. The administration has the ability in their authority now to implement a shared savings program. We've also seen some congressional activity around increasing ASP [average sales price] add-on for physicians, zero-dollar cost share for patients, Part D Star ratings measures around biosimilars. All of those things are really important to help get the market moving and stimulate the biosimilar market so that we not only have better uptake now, but that we have a long-term robust and sustainable market where we're truly driving down costs.


Click here to view Biosimilars CME Activities

Click here to view Biosimilars PTCE Activities

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars® is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2020 Intellisphere, LLC. All Rights Reserved.